Insilico Medicine, Inc.

Insilico Medicine develops artificial intelligence systems that utilize deep generative models, reinforcement learning (RL), transformers, and other modern machine learning techniques for the generation of new molecular structures with specific properties.

Insilico will lead by relentlessly innovating, publishing proofs of concept and delivering AI software that deploys the latest technology. A key concept to Insilico’s approach is ruthless internal competition, where different models compete against each other to rapidly prove which is superior and offers greater results. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trials outcomes.

Insilico’s capabilities can be leveraged by Juvenescence to speed hit-to-lead discovery.

For more information, please visit Insilico.com.